StreetInsider.com News Articles

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Tue, 03 Jun 2025 14:12:00 -0400

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal^® technology and Eli Lilly's proprietary drug compounds
Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty

LUND, Sweden and INDIANAPOLIS, June 3, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) and Eli Lilly and Company ("Lilly") have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, and commercialization of long-acting incretin products for cardiometabolic health based on

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Tue, 03 Jun 2025 14:12:00 -0400

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal^® technology and Eli Lilly's proprietary drug compounds
Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Tue, 03 Jun 2025 14:12:00 -0400

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal^® technology and Eli Lilly's proprietary drug compounds
Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Tue, 03 Jun 2025 14:12:00 -0400

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal^® technology and Eli Lilly's proprietary drug compounds
Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Tue, 03 Jun 2025 14:12:00 -0400

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal^® technology and Eli Lilly's proprietary drug compounds
Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Tue, 03 Jun 2025 14:12:00 -0400

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal^® technology and Eli Lilly's proprietary drug compounds
Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Tue, 03 Jun 2025 14:12:00 -0400

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal^® technology and Eli Lilly's proprietary drug compounds
Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Tue, 03 Jun 2025 14:12:00 -0400

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal^® technology and Eli Lilly's proprietary drug compounds
Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Tue, 03 Jun 2025 14:12:00 -0400

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal^® technology and Eli Lilly's proprietary drug compounds
Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Tue, 03 Jun 2025 14:12:00 -0400

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal^® technology and Eli Lilly's proprietary drug compounds
Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty

Camurus (CAMX) Announces CHMP recommends approval of Oczyesa for treatment of acromegaly in the EU

Fri, 25 Apr 2025 10:17:29 -0400

Camurus (NASDAQ: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for market authorization of Oczyesa^®, octreotide subcutaneous depot (CAM2029), for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.¹

"We are pleased with the CHMP's positive recommendation for market authorization for Oczyesa octreotide monthly depot for the treatment of acromegaly", says Fredrik Tiberg, President & CEO at Camurus. "Oczyesa has the potential to advance the standard of care for patients living with acromegaly

CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU